HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment
Journal of Cancer Research and Clinical Oncology · 2023
DOI: 10.1007/s00432-023-04574-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2023. Verfasst von Yihan Zhou. Beteiligte Einrichtung: Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, UK. yihan.zhou@oncology.ox.ac.uk. Hauptthemen laut MEDLINE: Breast Neoplasms, Triple Negative Breast Neoplasms, Vaccines, Cancer Vaccines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Constituting 15 to 20% of breast cancer cases, the triple-negative subtype lacks effective treatments as being less responsive to hormone-associated therapies. Alternatively, a more powerful immunotherapeutic vaccination can trigger immune recognition and destruction against breast cancer by incorporating oncological antigens such as human epidermal growth factor receptor 2 (HER2/neu). Currently, HER2/neu-based vaccines have finished three phases with breast cancer patients, in conjunction with granulocyte-macrophage colony-stimulating factor (GM-CSF) that was proven to be a promising vaccine adjuvant in other cancer trials previously.
Methods
Completed HER2/neu-based vaccine trials with GM-CSF immunoadjuvants for breast cancer were summarised, and additionally, the article discussed prominent findings of vaccine effectiveness in triple-negative breast cancer, regarding li-Key hybrid in vaccine design and co-administration of anti-HER2/neu trastuzumab.
Results
Nine clinical trials of three HER2/neu epitopes, one with li-Key hybrid, were analysed with or without the presence of trastuzumab. Immunological responses and minimal toxicities were observed in these epitopes, and disease-free survival was especially improved in the triple-negative population.
Conclusion
HER2/neu-based peptide vaccine is a safe and effective approach against breast cancer, and its benefits can be potentially furthered by combining the li-Key hybrid vaccine with targeted drugs and adjuvants selected to enhance cross-presentation for exogenous vaccine antigens. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, UK. yihan.zhou@oncology.ox.ac.uk.
Zitieren
APA
Zhou, Y. (2023). HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-04574-9
Vancouver
Zhou Y. HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment. Journal of Cancer Research and Clinical Oncology. 2023. doi:10.1007/s00432-023-04574-9
BibTeX
@article{Zhou2023,
author = {Zhou, Yihan},
title = {HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2023},
doi = {10.1007/s00432-023-04574-9}
}
EUVIMED